<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sutimlimab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sutimlimab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sutimlimab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="134963" href="/d/html/134963.html" rel="external">see "Sutimlimab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56582482"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Enjaymo</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56574203"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Complement C1 Inhibitor;</li>
<li>
                        Complement Inhibitor;</li>
<li>
                        Monoclonal Antibody;</li>
<li>
                        Monoclonal Antibody, Complement Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F56576948"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Vaccinate patients against encapsulated bacteria at least 2 weeks prior to sutimlimab initiation, according to the most current recommendations from the Advisory Committee on Immunization Practices for patients with persistent complement deficiencies, and revaccinate patients in accordance with those recommendations. Immunize patients without a history of vaccination against encapsulated bacteria at least 2 weeks prior to receiving the first sutimlimab dose; if urgent treatment with sutimlimab is indicated in an unvaccinated patient, administer vaccine(s) as soon as possible.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6763e47e-77f6-453d-922f-ab54f41f443e">Cold agglutinin disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cold agglutinin disease: Note: </b>Administer sutimlimab at the recommended dosage regimen time points, or within 2 days of these time points.</p>
<p style="text-indent:-2em;margin-left:4em;">39 kg to &lt;75 kg: <b>IV:</b> 6.5 g once weekly for 2 weeks (on days 0 and 7), followed with 6.5 g once every 2 weeks thereafter, beginning on day 21 (Röth 2021; Röth 2022; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">≥75 kg: <b>IV:</b> 7.5 g once weekly for 2 weeks (on days 0 and 7), followed with 7.5 g once every 2 weeks thereafter, beginning on day 21 (Röth 2021; Röth 2022; manufacturer's labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Discontinuation of therapy:</i> If sutimlimab treatment is interrupted, closely monitor patients for signs/symptoms of recurrent hemolysis, such as elevated total bilirubin levels or lactate dehydrogenase levels accompanied by a decrease in hemoglobin, or reappearance of symptoms such as fatigue, dyspnea, palpitations, or hemoglobinuria. Consider restarting sutimlimab if signs/symptoms of hemolysis occur after discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a sutimlimab dose is missed, administer as soon as possible; thereafter, resume dosing every 2 weeks. If the duration after the last dose exceeds 17 days, administer sutimlimab once weekly for 2 weeks, and return to every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56576950"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling; however, no clinically significant differences on sutimlimab pharmacokinetics were observed in mild or moderate impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling (effects are unknown).</p></div>
<div class="block doha drugH1Div" id="F56576951"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (effects are unknown).</p></div>
<div class="block dot drugH1Div" id="F56576952"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Autoimmune disease: Manage as medically appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Discontinue sutimlimab infusion and institute appropriate supportive management if signs of hypersensitivity reactions (eg, cardiovascular instability or respiratory compromise) occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion reaction: Slow or stop the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Infection, serious: Consider sutimlimab treatment interruption in patients who are being treated for serious infection.</p></div>
<div class="block doe drugH1Div" id="F56576949"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56713761"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Infections (eg, <b>bacterial infection,</b> otomastoiditis, <b>pneumonia,</b>
<b>skin infection,</b>
<b>urinary tract infection</b>, <b>viral infection</b>), including <b>serious infections</b> (eg, <b>sepsis</b>), have been reported. Sutimlimab may increase susceptibility to infections caused by encapsulated bacteria (eg, <i>Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae</i>) and may worsen preexisting active systemic infections.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action of sutimlimab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Unvaccinated against encapsulated bacteria</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reactions</b>, including flushing, <b>headache,</b>
<b>nausea</b>, rapid heartbeat, sensation of cold, shortness of breath, and stress cardiomyopathy, have been reported with sutimlimab. In clinical trials, all reactions were described as mild or moderate in severity and resolved within a day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33826820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33826820'])">Ref</a></span>). Infusion rate reduction, therapy interruption, and/or discontinuation may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33826820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33826820'])">Ref</a></span>); within 24 hours of initiation of infusion.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56576905"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, peripheral edema, Raynaud disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (including urinary tract infection with sepsis)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including bacterial infection and viral infection), serious infection (including otitis media [otomastoiditis], pneumonia, sepsis, and skin infection)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, fatigue (including asthenia and malaise), headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, cyanosis (acrocyanosis), nasopharyngitis, respiratory tract infection, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Immunologic: Autoimmune disease (relapse or worsening)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Increased serum creatinine</p></div>
<div class="block coi drugH1Div" id="F56574206"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to sutimlimab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F56576935"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disease: Based on the mechanism of action, sutimlimab has the potential to increase the risk for development of autoimmune diseases (eg, systemic lupus erythematosus [SLE]). The development of SLE has been associated with inherited classical complement deficiency. Patients with SLE or autoimmune disease with positive antinuclear antibody were excluded from sutimlimab clinical trials. A small percentage of patients experienced a relapse or worsening of preexisting autoimmune disease in clinical trials.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic infections: If not recognized and treated promptly, some infections could rapidly become life-threatening or fatal. The patient's immune status should be taken into consideration when initiating sutimlimab treatment. Sutimlimab has not been studied in patients with chronic systemic infections such as hepatitis B, hepatitis C, or HIV.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F56582483"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Enjaymo: Sutimlimab-jome 1100 mg/22 mL (22 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F56582481"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56599694"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Enjaymo Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1100MG/22ML (per mL): $104.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F56713931"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Available through specialty distributors. Information regarding distribution is available from the manufacturer at https://www.enjaymohcp.com/resources-for-your-practice.</p></div>
<div class="block adm drugH1Div" id="F56576953"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 1 to 2 hours (depending on patient weight; see tables). Administer via a 0.2 micron in-line filter with a polyethersulfone membrane. Prime the infusion tubing with the dosing solution immediately before infusion (if infusing undiluted, also prime infusion catheter); flush with a sufficient quantity of NS (~20 mL) immediately after completion of infusion.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Undiluted Sutimlimab Recommended Infusion Rates</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Body weight</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Sutimlimab dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Sutimlimab volume</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Maximum infusion rate</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> May infuse over 120 minutes in patients with cardiopulmonary disease.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39 kg to &lt;75 kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6.5 g</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130 ml</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130 mL/hour<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥75 kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7.5 g</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mL</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">150 mL/hour<sup>a</sup></p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Diluted Sutimlimab Recommended Infusion Rates</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Body weight</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Sutimlimab dose</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Total volume</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Maximum infusion rate</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> May infuse over 120 minutes in patients with cardiopulmonary disease.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39 kg to &lt;70 kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6.5 g</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500 mL</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">250 mL/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">70 kg to &lt;75 kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6.5 g</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500 mL</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500 mL/hour<sup>a</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥75 kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7.5 g</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500 mL</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500 mL/hour<sup>a</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">If refrigerated, allow the infusion solution (diluted or undiluted) to adjust to room temperature and administer within 8 hours. In-line infusion warmers may be utilized; do not exceed a temperature of 40°C (104°F). No incompatibilities have been observed between sutimlimab infusion solution and administration sets made of DEHP-plasticized PVC, DEHP-free polypropylene and polyethylene.</p>
<p style="text-indent:-2em;margin-left:2em;">If an infusion reaction occurs, slow or stop the infusion. Monitor during infusion and for at least 2 hours after the initial infusion for signs/symptoms of infusion and/or hypersensitivity reaction; monitor for 1 hour after subsequent infusions for signs/symptoms of infusion reaction.</p></div>
<div class="block meg drugH1Div" id="F56576930"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F761164s000lbl.pdf%23page%3D13&amp;token=7yfd7g9yHKFF3Qr4NeNWZoRrWAim8HRCHbjchVEWMpPrm8%2F17fPXzper%2FSMtd%2FD8K9AIj6UdfBUO%2FjH3%2FK0%2BKVcsk4pg%2BEuK6hWTnKJu7SVBSsRiINCGYhQveXdI8Ino&amp;TOPIC_ID=134951" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf#page=13</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F56574205"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cold agglutinin disease:</b> Treatment of hemolysis in adults with cold agglutinin disease.</p></div>
<div class="block mst drugH1Div" id="F56576929"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Enjaymo may be confused with Entyvio.</p>
<p style="text-indent:-2em;margin-left:4em;">Sutimlimab may be confused with sarilumab, siltuximab.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56594692"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56594689"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F56576933"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Sutimlimab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG crosses the placenta. Exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block brc drugH1Div" id="F56576934"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sutimlimab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Sutimlimab is a humanized monoclonal antibody (IgG<sub>4</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F56576955"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of infection; if sutimlimab is administered to patients with active systemic infections, monitor closely for worsening infection. Monitor for signs/symptoms of infusion and/or hypersensitivity reaction during infusion and for at least 2 hours after the initial infusion; monitor for 1 hour after subsequent infusions. Monitor for signs/symptoms of autoimmune disease. Upon treatment interruption or discontinuation, monitor for signs/symptoms of recurrent hemolysis (eg, elevated total bilirubin levels or lactate dehydrogenase [LDH] levels accompanied by a decrease in hemoglobin, or reappearance of symptoms such as fatigue, dyspnea, palpitations, or hemoglobinuria).</p></div>
<div class="block pha drugH1Div" id="F56576939"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sutimlimab is a humanized immunoglobulin G (IgG<sub>4</sub>) monoclonal antibody which targets and inhibits complement (Röth 2021). Sutimlimab inhibits the classical complement pathway by specifically binding to the complement protein component 1, s subcomponent (C1s), which is a serine protease that cleaves C4. Inhibition of the classical complement pathway at the C1s level prevents deposition of complement opsonins on RBC surfaces, resulting in inhibition of hemolysis in cold agglutinin disease. Sutimlimab does not inhibit the lectin and alternative pathways.</p></div>
<div class="block phk drugH1Div" id="F56576940"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Mean hemoglobin level increased by 1.2 g/dL within the first week and by ~2.3 g/dL by the third week (Röth 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~5.8 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via degradation into small peptides and individual amino acids.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 21 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: ~0.14 L/day.</p></div>
<div class="block phksp drugH1Div" id="F56576946"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Body weight: Population pharmacokinetic analysis demonstrated that sutimlimab AUC at steady state decreased up to 40% for a patient weighing 110 kg following the 7.5 g dose and increased up to 170% for a patient weighing 40 kg following the 6.5 g dose, when compared to a patient weighing 70 kg following the 6.5 g dose. Sutimlimab is dosed by weight ranges to accommodate for the effect of body weight on pharmacokinetics.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Enjaymo.1">
<a name="Enjaymo.1"></a>Enjaymo (sutimlimab) [prescribing information]. Waltham, MA: Bioverativ Therapeutics Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod ToxicolR</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33826820">
<a name="33826820"></a>Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in cold agglutinin disease. <i>N Engl J Med</i>. 2021;384(14):1323-1334. doi:10.1056/NEJMoa2027760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/33826820/pubmed" id="33826820" target="_blank">33826820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35687757">
<a name="35687757"></a>Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. <i>Blood</i>. 2022;140(9):980-991. doi:10.1182/blood.2021014955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/35687757/pubmed" id="35687757" target="_blank">35687757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sutimlimab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 134951 Version 49.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
